Patents Assigned to The MetroHealth System
  • Patent number: 11241189
    Abstract: A sensing device can be placed within the colon to study bowel function. The sensing device can include a flexible printed circuit board that includes at least one senor configured to record data related to bowel activity from a patient's colon; and a wireless transmitter configured to send the data from the patient's colon to an external device. The sensing device can also include at least one mucosal clip configured to fix the sensor board to a wall of the patient's colon for a measurement period. The flexible printed circuit board and/or the at least one mucosal clip are configured to be passed from the patient's colon after the measurement period through normal defecation.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: February 8, 2022
    Assignees: THE CLEVELAND CLINIC FOUNDATION, THE METROHEALTH SYSTEM, THE U.S. GOV'T AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS
    Inventors: Aref Smiley, Dennis Bourbeau, Margot S. Damaser, Steve Majerus, Massarat Zutshi, Ian Mcadams
  • Patent number: 10196441
    Abstract: The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain and a marked decrease in lipid synthesis and accumulation.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: February 5, 2019
    Assignee: THE METROHEALTH SYSTEM
    Inventors: M. Michael Wolfe, Michael O. Boylan
  • Patent number: 8651107
    Abstract: A manual lung ventilation device and method suitable for acute manual respiratory resuscitation and lung ventilation of a person are disclosed. The manual lung ventilation device includes a nasal interface in fluid communication with a flexible chamber. The nasal interface being held in the proper position on the person by a headgear and at least one securing device adapted to connect the nasal interface to the headgear. The device may be formed as a single component to allow an operator to rapidly position the device on the person to be ventilated and operate the device with one hand.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: February 18, 2014
    Assignee: The Metrohealth System
    Inventor: David J. Birnkrant
  • Publication number: 20100122699
    Abstract: A medical device and method for combination lung ventilation and mucus clearance of a patient is disclosed. The medical device may be configured to provide lung ventilation with intermittent, on-demand mucus clearance, freeing the patient's mouth for activities of daily living such as when the patient is awake; and, in another configuration, the device can provide lung ventilation with automated mucus clearance, such as when the patient is sedated or asleep. The medical device may comprise a pressure generation source, a ventilation portion, and a mucus clearance portion. The mucus clearance portion may be separable from or separate from the ventilation portion such that the medical device is capable of maintaining lung ventilation with the mouth interface removed from the patient.
    Type: Application
    Filed: November 17, 2009
    Publication date: May 20, 2010
    Applicant: The MetroHealth System
    Inventor: David J. Birnkrant
  • Patent number: 7625863
    Abstract: Isolated peptides and polynucleotides are provided that can be used to treat a subject that has a genetic predisposition to, or has been diagnosed as having, a cardiac disorder related to dysfunctional sodium channels. Also provided are methods of treatment, as well as methods of predicting the occurrence of a cardiac event or the severity or prognosis of cardiac symptoms, in a subject that has either been diagnosed as having, or is suspected of developing, a sodium channel related cardiac disorder, by testing the subject for the presence of H558R-polymorphism on the subject's SCN5A gene.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: December 1, 2009
    Assignee: The MetroHealth System
    Inventor: Isabelle Deschenes
  • Publication number: 20080214457
    Abstract: Isolated peptides and polynucleotides are provided that can be used to treat a subject that has a genetic predisposition to, or has been diagnosed as having, a cardiac disorder related to dysfunctional sodium channels. Also provided are methods of treatment, as well as methods of predicting the occurrence of a cardiac event or the severity or prognosis of cardiac symptoms, in a subject that has either been diagnosed as having, or is suspected of developing, a sodium channel related cardiac disorder, by testing the subject for the presence of H558R-polymorphism on the subject's SCN5A gene.
    Type: Application
    Filed: October 29, 2007
    Publication date: September 4, 2008
    Applicant: THE METROHEALTH SYSTEM
    Inventor: Isabelle Deschenes
  • Publication number: 20080092895
    Abstract: A manual lung ventilation device and method suitable for acute manual respiratory resuscitation and lung ventilation of a person are disclosed. The manual lung ventilation device includes a nasal interface in fluid communication with a flexible chamber. The nasal interface being held in the proper position on the person by a headgear and at least one securing device adapted to connect the nasal interface to the headgear. The device may be formed as a single component to allow an operator to rapidly position the device on the person to be ventilated and operate the device with one hand.
    Type: Application
    Filed: October 19, 2007
    Publication date: April 24, 2008
    Applicant: THE METROHEALTH SYSTEM
    Inventor: David J. Birnkrant
  • Patent number: 7060794
    Abstract: The present invention provides polynucleotides that encode a protein, designated herein as K+ Channel Associated Protein or “KChAP”. It has been determined that expressing polynucleotides that encode KChAP in host cells, along with polynucleotides that encode the Kv? channel subunit Kv 2.1, the Kv? channel subunit Kv 2.2, the Kv? channel subunit Kv 1.3, or the Kv? channel subunit Kv 4.3, increases the number of Kv2.1, Kv 2.2, Kv1.3 or Kv4.3 channels, respectively, in the plasma membrane of such cells. The present invention also relates to a method of making cells that have increased numbers of Kv channels on the plasma membranes thereof and to a method of using such cells as model systems for studying the effect of pharmacological agents on Kv channels, particularly on Kv2.1, Kv 2.2, Kv 1.3, and Kv 4.3 channels. The present invention also relates to the protein KChAP.
    Type: Grant
    Filed: February 13, 2002
    Date of Patent: June 13, 2006
    Assignee: The MetroHealth System
    Inventors: Arthur M Brown, Barbara A Wible, Qing Yang
  • Patent number: 6391561
    Abstract: The present invention provides polynucleotides that encode a protein, designated herein as K+ Channel Associated Protein or “KChAP”. It has been determined that expressing polynucleotides that encode KChAP in host cells, along with polynucleotides that encode the Kv&agr; channel subunit Kv 2.1, the Kv&agr; channel subunit Kv 2.2, the Kv&agr; channel subunit Kv 1.3, or the Kv&agr; channel subunit Kv 4.3, increases the number of Kv2.1, Kv 2.2, Kv1.3 or Kv4.3 channels, respectively, in the plasma membrane of such cells. The present invention also relates to a method of making cells that have increased numbers of Kv channels on the plasma membranes thereof and to a method of using such cells as model systems for studying the effect of pharmacological agents on Kv channels, particularly on Kv2.1, Kv 2.2, Kv 1.3, and Kv 4.3 channels. The present invention also relates to the protein KChAP.
    Type: Grant
    Filed: November 14, 2000
    Date of Patent: May 21, 2002
    Assignee: The MetroHealth System
    Inventors: Arthur M. Brown, Barbara A. Wible, Qing Yang
  • Patent number: 6207422
    Abstract: The present invention provides polynucleotides that encode a protein, designated herein as K+ Channel Associated Protein or “KChAP”. It has been determined that expressing polynucleotides that encode KChAP in host cells, along with polynucleotides that encode the Kv&agr; channel subunit Kv 2.1, the Kv&agr; channel subunit Kv 2.2, the Kv&agr; channel subunit Kv 1.3, or the Kv&agr; channel subunit Kv 4.3, increases the number of Kv2.1, Kv 2.2, Kv1.3 or Kv4.3 channels, respectively, in the plasma membrane of such cells. The present invention also relates to a method of making cells that have increased numbers of Kv channels on the plasma membranes thereof and to a method of using such cells as model systems for studying the effect of pharmacological agents on Kv channels, particularly on Kv2.1, Kv 2.2, Kv 1.3, and Kv 4.3 channels. The present invention also relates to the protein KChAP.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: March 27, 2001
    Assignee: The MetroHealth System
    Inventors: Arthur M. Brown, Barbara A. Wible, Qing Yang
  • Patent number: 5733889
    Abstract: The present invention provides a novel treatment for cardiac arrhythmias, by administering S-adenosyl methionine decarboxylase inhibitors, preferably 5'-({(Z)-4-amino-2-butenyl}methylamino)-5'-deoxyadenosine. It has been discovered that 5'-({(Z)-4-amino-2-butenyl}methylamino)-5'-deoxyadenosine, increases the P--R interval, increases outward current through inward rectifier K.sup.+ channels and increases the hyperpolarization, of cardiac cells, thereby reducing cardiac excitability. Specifically, the method involves providing an S-adenosyl methionine decarboxylase inhibitor; combining the S-adenosyl methionine decarboxylase inhibitor with a pharmaceutically acceptable carrier to provide a pharmaceutical composition; administering an effective amount of the pharmaceutical composition to a patient suffering from a cardiac arrhythmia, wether such arrhythmias are induced by disease or cardiotoxicity.
    Type: Grant
    Filed: October 29, 1996
    Date of Patent: March 31, 1998
    Assignee: The MetroHealth System
    Inventor: Arthur M. Brown
  • Patent number: 5487889
    Abstract: The present invention provides a biological bandage, comprising an envelope enclosing cells which secrete biologically active cellular products such as growth factors, which promote the healing of wounds. The envelope is further comprised of a permeable bottom membrane through which the cellular product diffuses, and a top membrane. Preferably the bandage has a separator interposed between the two membranes. This invention also relates to a method for treating wounds. The bandage provides a continuous, uniform source of fresh cellular product.
    Type: Grant
    Filed: August 13, 1993
    Date of Patent: January 30, 1996
    Assignees: The MetroHealth System, The University of Akron, Case Western Reserve University
    Inventors: Richard L. Eckert, Daniel J. Smith, Irwin Schafer